Clinical Trials Logo

Neoplasm Metastasis clinical trials

View clinical trials related to Neoplasm Metastasis.

Filter by:

NCT ID: NCT01894633 Terminated - Brain Metastasis Clinical Trials

Study of Whole-brain Irradiation With Chloroquine for Brain Metastases

CLQ
Start date: May 2011
Phase: Phase 2
Study type: Interventional

Background and purposes:Chloroquine (CLQ), an antimalarial drug, has a lysosomatrophic effect associate with increase the sensibility of Radiation through leakage of hidroliticenzimes, increase of apoptosis, autophagy mediated by lysosomalhidrolases and increase of oxidative stress "in vitro". In this phase II study we evaluated the efficacy and safety as radiosensitizing of the Chloroquine plus concomitant 30 Gray (Gy) of Whole-brain irradiation (WBI)in patients with brain metastases (BM) from solid tumors.

NCT ID: NCT01855061 Terminated - Neoplasm Metastasis Clinical Trials

Biomarker Development for Response Prediction by DNA Mutational Analysis

CPCT-01
Start date: May 2011
Phase: N/A
Study type: Observational

The purpose of this study is to determine whether it is possible to predict response to chemotherapy in patients with metastatic cancer who are treated with irinotecan by determining the mutational profile of the tumor.

NCT ID: NCT01849744 Terminated - Metastatic Cancer Clinical Trials

Phase I Dose Escalation Study of VS-4718 in Subjects With Metastatic Non-Hematologic Malignancies

Start date: June 2013
Phase: Phase 1
Study type: Interventional

This is a Phase I, open-label, multicenter, dose-escalation trial of VS-4718, a focal adhesion kinase inhibitor, in subjects with metastatic non-hematologic malignancies. This clinical study is comprised of 2 parts: Part 1 (Dose Escalation) and Part 2 (Expansion). The purpose of this study is to evaluate the safety (including the recommended Phase II dose), pharmacokinetics (the amount of VS-4718 in your blood) and the anti-cancer activity of VS-4718. The pharmacodynamic effects (genes or proteins that may predict or show how your body may respond to VS-4718) will also be examined in tumor biopsies and blood samples.

NCT ID: NCT01846429 Terminated - Pain Clinical Trials

Oral Bicarbonate as Adjuvant for Pain Reduction in Patients With Tumor Related Pain

Start date: September 2013
Phase: Phase 1
Study type: Interventional

The purpose of this study is to: - Determine how well people tolerate sodium bicarbonate taken by mouth in higher doses than those usually given for heartburn. - Determine if sodium bicarbonate can reduce cancer-related pain.

NCT ID: NCT01842971 Terminated - Colorectal Cancer Clinical Trials

ALPPS (Liver Partition and Portal Vein Ligation) for Two-stage Hepatectomy for Colorectal Liver Metastasis

Start date: June 7, 2013
Phase: Phase 3
Study type: Interventional

The aim of this study is evaluate the feasibility of early two-stage hepatectomy in patients with liver metastasis from colorectal cancer.

NCT ID: NCT01834937 Terminated - Clinical trials for Pain Resulting From Bone Metastases

ExAblate Treatment of Metastatic Bone Tumors for the Palliation of Pain

BM019-Registry
Start date: June 2013
Phase:
Study type: Observational [Patient Registry]

The purpose of this enhanced surveillance study ("ESS") is to collect information regarding chronic adverse events that are possibly related to the ExAblate® System ("ExAblate") that are received by InSightec ("InSightec") following PMA approval. This study will examine adverse events reported in patients undergoing the device procedure for the first two years of commercial experience. Other relevant data may be collected as well.

NCT ID: NCT01821443 Terminated - Brain Metastases Clinical Trials

A Single Arm Study of Neurocognitive Outcomes in Patients With Brain Metastases Managed With Stereotactic Radiosurgery (SRS)

Start date: December 2012
Phase: N/A
Study type: Interventional

The purpose of this study is to find out what effects, good and/or bad, stereotactic radiosurgery (Gamma knife) has on brain metastasis(es). Gamma knife radiosurgery is a way of giving radiation therapy to the brain in a very focused way, so that nearby parts of the brain receive very little exposure to radiation. No incisions are involved. Imaging technology is used to pinpoint the location of the tumor. In this study, the investigators are also trying to find out how the tumor and/or treatment affect brain function over time. The investigators will do this by performing a series of neurocognitive assessments, or tests of memory, reasoning, and higher brain function, before treatment and at regular intervals after treatment.

NCT ID: NCT01767935 Terminated - Pain Clinical Trials

Cryosurgery and Radiation Therapy in Treating Patients With Painful Bone Metastases

Start date: July 2014
Phase: N/A
Study type: Interventional

This pilot clinical trial studies cryosurgery and radiation therapy in treating patients with painful bone metastases. Cryosurgery kills tumor cells by freezing them. Radiation therapy uses high-energy x-rays and other types of radiation to kill tumor cells and shrink tumors. Giving cryosurgery together with radiation therapy may kill more tumor cells

NCT ID: NCT01759238 Terminated - Colorectal Cancer Clinical Trials

Chemoradiotherapy for Patients With Oligometastatic Colorectal Cancer

OLGA
Start date: May 2013
Phase: Phase 2
Study type: Interventional

This study tries to evaluate the role of chemoradiation with capecitabine and bevacizumab in oligometastatic patients neither being progressive nor resectable after chemotherapy.

NCT ID: NCT01730157 Terminated - Liver Metastases Clinical Trials

Radioembolization and Ipilimumab in Treating Patients With Uveal Melanoma With Liver Metastases

Start date: December 2012
Phase: Phase 0
Study type: Interventional

This pilot clinical trial studies radioembolization and ipilimumab in treating patients with uveal melanoma with liver metastases. Radioembolization kills tumor cells by blocking the blood flow to the tumor and keeping radioactive substances near the tumor. Monoclonal antibodies, such as ipilimumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Giving radioembolization together with ipilimumab may kill more tumor cells in patients with uveal melanoma